Stock analysts at Wedbush assumed coverage on shares of Novan Inc (NASDAQ:NOVN) in a report issued on Monday, The Fly reports. The firm set an “outperform” rating on the stock.

Separately, Piper Jaffray Cos. initiated coverage on shares of Novan in a research note on Monday. They set an “overweight” rating for the company.

Novan (NASDAQ:NOVN) opened at 18.97 on Monday. The stock’s 50 day moving average is $19.79 and its 200-day moving average is $19.79. Novan has a 12-month low of $13.77 and a 12-month high of $23.79. The company’s market cap is $46.42 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

In other news, major shareholder Life Sciences Holdings L. Malin acquired 800,000 shares of the firm’s stock in a transaction that occurred on Monday, September 26th. The stock was purchased at an average price of $11.00 per share, for a total transaction of $8,800,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Novan Company Profile

Novan, Inc is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs).

5 Day Chart for NASDAQ:NOVN

The Fly

Receive News & Ratings for Novan Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novan Inc and related companies with's FREE daily email newsletter.